ClinicalTrials.gg
RecruitingNCT06993636Updated May 29, 2025

Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years

An observational study in Kawasaki Disease, Coronary Artery Aneurysm and Rivaroxaban, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Children's Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University — 5 open to participants now, 5 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · Children's Hospital of Fudan University.

Started
2023
the only one that year
Observational
4 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, this one is the only one that started in 2023, is one of 4 observational ones, and was the 8th registered.

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

Browse Mucocutaneous Lymph Node Syndrome studies →

Open to participants now

5 of the 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Mucocutaneous Lymph Node Syndrome by Children's Hospital of Fudan University, or all of them as a file.
02

Study summary

Based on an established Kawasaki disease cohort database, this prospective, single-center, single-arm, observational study will collect clinical data from children aged 2 years and older with giant coronary artery aneurysms after Kawasaki disease who received rivaroxaban treatment. Rivaroxaban plasma concentrations, anti-factor Xa activity levels, and genetic polymorphisms will be measured and analyzed to support the population pharmacokinetic/pharmacodynamic analysis

03

Conditions studied

  • Kawasaki Disease
  • Coronary Artery Aneurysm
  • Rivaroxaban
  • Anticoagulant Drugs
  • Pharmacokinetics and Pharmacodynamics

Keywords

  • Kawasaki disease
  • Coronary artery aneurysm
  • Population pharmacokinetic and pharmacodynamic
  • rivaroxaban
  • anticoagulant
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children aged ≥2 years with giant coronary artery aneurysms after Kawasaki disease treated with rivaroxaban at the Children's Hospital of Fudan University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Giant coronary artery aneurysm(s) in any coronary artery after acute stage of Kawasaki disease. Giant coronary artery aneurysm(s) should be confirmed by two-dimensional echocardiography and meet the diagnostic criteria of Z-score ≥10 or coronary artery internal diameter ≥8mm;
  2. Anticoagulant with antiplatelet drug therapy for anti-thromboprophylaxis is recommended for the next 6 months;
  3. Children aged 2 years to \<18 years

Exclusion criteria

Exclusion Criteria:

  1. Active bleeding or bleeding risk contraindicating anticoagulant therapy
  2. or any other listed in the local labeling for the comparator treatment or experimental treatment
  3. Patients participating in clinical trials of other drugs at the same time
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rivaroxaban

    Rivaroxaban as anticoagulant will be administered with antiplatelet drug for long-term antithrombotic treatment, following a model-based optimized dosing regimen. Rivaroxaban plasma concentration and rivaroxaban-calibrated Anti-FXa activity are measured for clinical monitoring

06

What researchers measure

Primary outcomes

  1. Rivaroxaban plasma concentration

    Opportunistic blood sampling will be performed at multiple predefined time points based on the principle of sparse sampling. It includes: 1. Day 1, 20 minutes -1 h after the first dose; 2. Day 1, 7±1 h after the first dose; 3. After at least three continuous doses (≥ Day 4): before the scheduled dose at that day, which is defined as the trough concentration; 4. After at least three continuous doses (≥ Day 4): 3±1 h the scheduled dose at that day, which is defined as the peak concentration. And peak and trough concentrations will be re-measured after each dose adjustment

    Time frame: From baseline to 6 months after rivaroxaban initiation, with scheduled sampling at the first hospitalization

  2. Rivaroxaban-calibrated anti-activated Factor X (FXa) activity

    Opportunistic blood sampling will be performed at multiple predefined time points based on the principle of sparse sampling. It includes: 1. Day 1, 20 minutes -1 h after the first dose; 2. Day 1, 7±1 h after the first dose; 3. After at least three continuous doses (≥ Day 4): before the scheduled dose at that day, which is defined as the trough concentration; 4. After at least three continuous doses (≥ Day 4): 3±1 h the scheduled dose at that day, which is defined as the peak concentration. And peak and trough concentrations will be re-measured after each dose adjustment

    Time frame: From baseline to 6 months after rivaroxaban initiation, with anti-FXa activity measured at the same time points as plasma concentration

Secondary outcomes

  1. Occurrence of new thrombosis in coronary arteries

    It is binary variable. Every echocardiography conducted during study period will be documented. Researcher will document whether new thrombosis occurs in coronary arteries, and record the number of involved coronary arteries.

    Time frame: From baseline to 6 months after rivaroxaban initiation

  2. Composite of Major bleeding or Clinically relevant non-major bleeding event

    It is a binary variable. Researcher will document major bleeding or clinically relevant non-major bleeding events. Major bleeding is defined as 1.Fatal bleeding; 2.Clinically overt bleeding associated with a decrease in Hemoglobin of ≥20 g/L in a 24-h period; 3.Critical site bleeding, such as retroperitoneal, pulmonary, pericardial, intracranial, or otherwise involves the central nervous system; 4.Bleeding that requires an intervention via an invasive procedure; 5.Overt bleeding for which a reversal agent is administered. Clinically relevant non-major bleeding event is defined as 1.Bleeding that results in a medical or procedural intervention not meeting major bleeding criteria, including a medication change (reducing, holding, or changing anticoagulation or addition of new medication) ; 2.Bleeding that results in hospitalization or increased level of care; 3.Overt bleeding for which a blood product is administered, and does not meet the criteria for major bleeding

    Time frame: From baseline to 6 months after rivaroxaban initiation

Other outcomes

  1. Genetic polymorphism

    Opportunistic sampling will be performed using the remaining blood specimens collected for rivaroxaban plasma concentration measurement. Genetic polymorphisms related to rivaroxaban metabolism and transport will be examined, including CYP3A4, ABCB1, ABCG2, and et.cl CYP3A4: Cytochrome P450 Family 3 Subfamily A Member 4, ABCB1: ATP Binding Cassette Subfamily B Member 1; ABCG2: ATP Binding Cassette Subfamily G Member 2

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
May 29, 2025
StartActual
Jan 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06993636
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jan 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 29, 2025

Study contacts

Fang Liu, MD
Contact
liufang@fudan.edu.cn
18017590880
Guangan Dai, MD
Contact
gadai24@m.fudan.edu.cn
13580762996
Fang Liu, MD
study director · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion